Study guide
15.3 Transfusion-Transmitted Diseases
Specialist in Blood Banking, SBB ASCP
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 Current Exam Facts 1.2 Eligibility Routes & Credential Maintenance 1.3 Study Strategy for SBB
2 Donors & Collection
2.1 Donor Qualification 2.2 Collection Methods & Adverse Reactions 2.3 Special Donations
3 Processing, Storage & Component QC
3.1 Processing, Testing & Labeling 3.2 Storage, Transport & Expiration 3.3 Blood Component Quality Control
4 Red Cell & Modified Components
4.1 Whole Blood & Red Blood Cells 4.2 Leukocyte-Reduced, Washed, Frozen & Rejuvenated RBCs 4.3 Irradiated Components 4.4 Granulocytes
5 Platelets, Plasma & Cellular Products
5.1 Platelets 5.2 Plasma & Cryoprecipitated AHF 5.3 Apheresis Products & Fractionation Products 5.4 Hematopoietic Progenitors
6 Genetics, ABO & Rh
6.1 Blood Group Genetics & Molecular Inheritance 6.2 ABO & Lewis Systems 6.3 Rh System 6.4 MNS, P1PK/Globoside & Ii
7 Other Blood Groups & Role in Transfusion
7.1 Kell, Kidd, Duffy & Lutheran 7.2 Other Systems & High/Low-Prevalence Antigens 7.3 HLA, Platelet-Specific & Granulocyte Antigens 7.4 Immunogenicity & Antigen Prevalence
8 Immunology Foundations
8.1 Immune Response 8.2 Immunoglobulins 8.3 Antigen-Antibody Interactions 8.4 Complement
9 Physiology, Hemostasis & HDFN
9.1 Physiology of Blood 9.2 Hemostasis and Coagulation 9.3 HDFN Pathophysiology & Detection 9.4 HDFN Treatment & Prevention
10 Cytopenias & Transplantation
10.1 Immune & Nonimmune Anemia 10.2 Thrombocytopenia & Neutropenia 10.3 Solid Organ Transplantation Support 10.4 Hematopoietic Progenitor Cell Transplantation
11 Routine Serologic Testing
11.1 Blood Grouping Tests 11.2 Antibody Detection & Crossmatch 11.3 Antibody Identification & Clinical Significance 11.4 Direct Antiglobulin Testing & Reagents
12 Special Serologic Methods
12.1 Enzymes, Enhancement Media & Lectins 12.2 Adsorptions, Elutions & Titrations 12.3 Cell Separations, Neutralization & Thiol Reagents 12.4 Chloroquine Diphosphate & EDTA-Glycine Acid
13 Molecular Platforms & Serologic QA
13.1 Molecular Blood Group Techniques 13.2 ELISA, Immunofluorescence, Solid Phase & Column Agglutination 13.3 Serologic Quality Assurance
14 Indications, Component Therapy & PBM
14.1 Indications for Transfusion 14.2 Component Therapy 14.3 Blood Administration & Patient Blood Management
15 Adverse Effects of Transfusion
15.1 Immunologic Transfusion Reactions 15.2 Nonimmunologic Reactions 15.3 Transfusion-Transmitted Diseases
16 Apheresis & Extracorporeal Circulation
16.1 Therapeutic Apheresis 16.2 Extracorporeal Circulation
17 Quality, Safety, Math & Instrumentation
17.1 Quality Assessment & Troubleshooting 17.2 Laboratory Safety 17.3 Laboratory Mathematics 17.4 Instrumentation
18 Laboratory Administration (SBB Only)
18.1 Financial Management 18.2 Operations & Information Technology 18.3 Personnel, Education & Training 18.4 Quality Management, Risk & Tissue Management
15.3 Transfusion-Transmitted Diseases
Key Takeaways Explain This Topic AI
Residual transfusion-transmission risk exists because of the window period between infection and detectable markers; nucleic acid testing (NAT) has shortened window periods for HIV, HBV, and HCV
Bacterial contamination is the leading infectious cause of transfusion-transmitted death; platelets are highest risk due to room-temperature storage, while Yersinia enterocolitica is the classic cold-growing contaminant of refrigerated RBCs
Viral agents are controlled primarily through serology plus NAT; CMV risk to vulnerable recipients is addressed with leukoreduced or CMV-seronegative components
Parasitic and prion agents without a practical screening test, such as malaria and variant Creutzfeldt-Jakob disease, are controlled through donor deferral rather than laboratory testing
Pathogen reduction technology provides a pathogen-agnostic safeguard for platelets and plasma, complementing testing and deferral strategies
Last updated: July 2026
15.3 Transfusion-Transmitted Diseases
Every unit of blood carries a small, but never entirely eliminated, residual risk of transmitting an infectious agent. This section covers the concept of residual risk, the pathogens of greatest concern, and how donor screening, laboratory testing, and pathogen reduction technology mitigate — without completely removing — that risk.
The Window Period and Residual Risk
Donor screening for transfusion-transmissible infections combines a health history questionnaire, serologic (antibody/antigen) testing, and nucleic acid testing (NAT). Even a technically negative donor can transmit infection during the window period — the interval after infection but before the marker being tested for becomes detectable. NAT, which detects viral genetic material directly rather than waiting for an antibody response, has shortened window periods dramatically compared with serology alone; for HIV, NAT narrows the window from roughly three to four weeks with antibody testing to about a week to ten days. Because a window period can never be reduced to zero, transfusion medicine describes residual risk — the very small, ongoing probability that a unit tests negative on all required assays yet is still infectious. Current estimated per-unit residual risks for HIV, HCV, and HBV in the United States are each on the order of one in several hundred thousand to roughly one in a million or better, reflecting the layered effect of questionnaire deferral, serology, and NAT; the exact order of magnitude shifts as testing technology improves, so SBB-level understanding should focus on the concept and the relative ranking of risk rather than a single fixed number.
Bacterial Contamination
Bacterial contamination is the most common infectious cause of transfusion-transmitted fatality because, unlike most viruses, bacteria can actively multiply in a stored blood component. Platelets carry the highest risk because they are stored at room temperature (20 to 24°C), an ideal growth temperature for many organisms, typically introduced from skin flora at the venipuncture site despite use of a diversion pouch to divert the first, most heavily skin-flora-contaminated milliliters away from the collection bag. Red blood cells are refrigerated and therefore lower risk overall, but psychrotrophic (cold-growing) organisms — classically Yersinia enterocolitica — can proliferate slowly during standard RBC storage; Yersinia is notable because it can enter a donor's bloodstream transiently via asymptomatic gastrointestinal translocation.
Detection and mitigation strategies include:
Culture-based testing — automated systems sampling the platelet unit approximately 24 hours after collection, sometimes paired with a later secondary rapid test, to detect and remove contaminated units before or during the storage period.
Pathogen reduction technology — treatments such as amotosalen/UV-A or riboflavin/UV light applied to platelets and plasma, which inactivate a broad range of bacteria, many viruses, and parasites, and in some jurisdictions serve as an alternative to gamma irradiation for preventing TA-GVHD.
Visual inspection of a unit before issue for clots, abnormal color, or hemolysis, which can suggest contamination.
A septic transfusion reaction from a contaminated unit presents with high fever, rigors, and rapid-onset hypotension or shock — gram-negative organisms are especially dangerous because of endotoxin release — and can be difficult to distinguish clinically from AHTR. The workup overlaps significantly: stop the transfusion, culture both the residual unit and the patient's blood, Gram stain the unit, and begin empiric broad-spectrum antibiotics while providing hemodynamic support.
Viral Agents
- Agent Key transfusion-medicine point
- HIV Serology plus NAT; NAT dramatically shortens the window period
Hepatitis B (HBV) Screened with surface antigen, core antibody, and NAT; occult HBV infection (low-level DNA with a negative surface antigen) is a recognized residual-risk challenge
- Hepatitis C (HCV) Antibody plus NAT; NAT closed most of the prior window-period gap
- HTLV-I/II Associated with adult T-cell leukemia/lymphoma and HAM/TSP; screened by antibody testing
Cytomegalovirus (CMV) Risk mainly to immunocompromised recipients, transplant recipients, and low-birth-weight neonates; leukoreduced components are generally considered comparable to CMV-seronegative components because CMV in immunocompetent donors is cell-associated
West Nile virus (WNV) NAT screening implemented following outbreaks; transmitted through mosquito-borne exposure in donors
- Zika virus Screened by NAT and donor deferral during recognized outbreak periods
- Parasitic and Prion Agents
Babesia microti (babesiosis) — a tick-borne intraerythrocytic parasite; donors can be asymptomatically parasitemic. FDA-licensed antibody/NAT screening is used in recognized endemic regions because Babesia survives standard refrigerated RBC storage.
Trypanosoma cruzi (Chagas disease) — U.S. donors are screened with a one-time antibody test at first donation, since past infection confers lifelong risk of transmission through chronic parasitemia.
Malaria (Plasmodium species) — no licensed screening test is used for U.S. blood donations; risk is instead managed entirely through travel- and residence-based donor deferral for defined periods after living in or visiting endemic areas.
Variant Creutzfeldt-Jakob disease (vCJD, a prion disease) — no validated blood screening test exists; risk is managed through geographic and time-based donor deferral, such as deferring donors with cumulative residence or travel history in regions with recognized bovine spongiform encephalopathy exposure.
Why No Single Strategy Is Sufficient
Each transfusion-transmitted disease is controlled by whichever combination of strategies fits its biology: testing (serology/NAT) works well for agents with a reliably detectable marker (HIV, HBV, HCV, WNV, Babesia); donor deferral is used when no practical test exists or when a test would be too insensitive (malaria, vCJD); and pathogen reduction/inactivation provides a pathogen-agnostic backstop for platelets and plasma. Recognizing which category a given agent falls into — tested, deferred, or inactivated — is a frequently tested SBB concept, since the choice not to simply test for an agent like malaria hinges on test sensitivity, specificity, and cost, rather than a lack of concern for the pathogen.